There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that combines powerful efficacy and favorable safety profil…
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad expression of FAP demonstrated in tumors or in tumor str…
Basel, March 23, 2021 — On Saturday, March 6, 2021, SonntagsBlick published an interview with Novartis Chairman Joerg Reinhardt, Ph.D., in connection with the 25th anniversary of the founding of the company. In the interview, Mr. Reinhardt was asked ab…
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer1VISION…
Today, on World Water Day, Novartis inaugurated an integrated watershed development project to help address water scarcity in the Telangana region of India, one of the world’s most water-stressed countries.Managed jointly with the …
Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective May 15, 2021….
The third annual Co-Creating Impact Summit in collaboration with Novartis’ Impact Valuation Advisory Council – chaired by John Elkington – brought together internal and external thought leaders in the area of ESG, sustainability and impact valuation to…
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, treatment-related adverse events Real-world data indica…
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments1Canakinumab development program continues; two P…
The COVID-19 pandemic created a number of different challenges for the patient community. Through those challenges, however, came opportunities to utilise digital engagement, and an accelerated use of digital tools. Participants of the European Patient…
